Compounds > triazoles
Page last updated: 2024-08-24

triazoles and mre 3008-f20

triazoles has been researched along with mre 3008-f20 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baraldi, PG; Borea, PA; Cacciari, B; Gessi, S; Hickey, SL; Leung, E; Merighi, S; Romagnoli, R; Spalluto, G; Varani, K1
Baraldi, PG; Borea, PA; Cacciari, B; Gessi, S; Klotz, KN; Leung, E; Merighi, S; Romagnoli, R; Spalluto, G; Varani, K1
Baraldi, PG; Borea, PA; Ferrari, D; Gessi, S; Leung, E; Merighi, S; Morelli, A; Spalluto, G; Varani, K1
Borea, PA; Cattabriga, E; Gessi, S; Iannotta, V; Leung, E; Merighi, S; Ulouglu, C; Varani, K1
Baraldi, PG; Borea, PA; Cattabriga, E; Gessi, S; Iannotta, V; Leung, E; Merighi, S; Varani, K1
Baraldi, PG; Borea, PA; Gessi, S; Klotz, KN; Leung, E; Merighi, S; Varani, K1
Benini, A; Borea, PA; Gessi, S; Leung, E; Maclennan, S; Merighi, S; Mirandola, P; Varani, K1
Gao, ZG; Jacobson, KA; Jeong, LS; Kim, SK1

Other Studies

8 other study(ies) available for triazoles and mre 3008-f20

ArticleYear
Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors.
    Bioorganic & medicinal chemistry letters, 2000, Feb-07, Volume: 10, Issue:3

    Topics: Animals; CHO Cells; Cricetinae; Humans; Phenylurea Compounds; Purinergic P1 Receptor Antagonists; Radioligand Assay; Receptor, Adenosine A3; Receptors, Purinergic P1; Recombinant Proteins; Triazoles; Tritium

2000
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Molecular pharmacology, 2000, Volume: 57, Issue:5

    Topics: Adenosine; Adenylyl Cyclase Inhibitors; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Phenylurea Compounds; Purinergic P1 Receptor Antagonists; Radioligand Assay; Rats; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles; Tritium

2000
Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.
    British journal of pharmacology, 2001, Volume: 134, Issue:1

    Topics: Animals; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Dose-Response Relationship, Drug; Guanosine Triphosphate; Humans; Jurkat Cells; Kinetics; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Pyrimidines; Receptor, Adenosine A2A; Receptor, Adenosine A3; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes; Thermodynamics; Time Factors; Triazoles; Tritium; Xanthines

2001
Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.
    British journal of pharmacology, 2001, Volume: 134, Issue:6

    Topics: Adenosine Deaminase; Binding, Competitive; Calcium; Cell Membrane; Cyclic AMP; Humans; Melanoma, Experimental; Phenylurea Compounds; Purinergic P1 Receptor Antagonists; Pyrimidines; Radioligand Assay; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Triazoles; Tritium; Tumor Cells, Cultured; Xanthines

2001
A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study.
    Molecular pharmacology, 2002, Volume: 61, Issue:2

    Topics: Adenosine; Binding, Competitive; Biological Transport; Calcium; Cyclic AMP; Gene Expression; Granulocytes; HL-60 Cells; Humans; Neutrophils; Phenylurea Compounds; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Superoxides; Triazoles

2002
Binding thermodynamics at the human A(3) adenosine receptor.
    Biochemical pharmacology, 2002, Jan-15, Volume: 63, Issue:2

    Topics: Adenosine; Animals; Cells, Cultured; CHO Cells; Cricetinae; Humans; Kinetics; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Thermodynamics; Transfection; Triazoles

2002
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells.
    Biochemical pharmacology, 2006, Jun-28, Volume: 72, Issue:1

    Topics: Adenosine; Adenosine A3 Receptor Antagonists; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Receptor, Adenosine A3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Triazoles; Up-Regulation; Vascular Endothelial Growth Factor A

2006
Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.
    Journal of molecular graphics & modelling, 2006, Volume: 25, Issue:4

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Binding Sites; Computer Simulation; Humans; Hydrogen Bonding; Imidazoles; In Vitro Techniques; Ligands; Models, Molecular; Phenylurea Compounds; Protein Conformation; Purines; Rats; Receptor, Adenosine A3; Receptor, Muscarinic M3; Structure-Activity Relationship; Triazoles

2006